Viscothionin Suppresses Human Non-small Cell Lung Cancer via Inhibiting the STAT3 Signaling Pathway
European Journal of Medicinal Plants,
Lung cancer is a crucial cause of mortality world-wide. Signal transducer and activator of transcription 3 (STAT3) are important signaling factors in malignant diseases and are constantly activated in 22% ~ 65% of non-small cell lung cancer (NSCLC) cells. STAT3 can be activated by interleukin-6 (IL-6) which induces cell growth in various cancer cells. Although viscothionin is studied for various health beneficial effects, the anticancer effect of viscothionin has not been studies so far against lung cancer. Therefore, the purpose of this study was to demonstrate the anticancer effect of a polypeptide, viscothionin in NCI-H460 lung cancer cells, which represents NSCLC. To do this, cultured NCI-H460 cells were treated with viscothionin and/or IL-6, and the cell viability, as well as expression levels of STAT3, Akt, mTOR, Bax, Bcl-2, and Bcl-xL, including caspase-3 after activity were assessed. As a result, cell viability was decreased in the viscothionin-treated group as compared to control. Also, viscothionin significantly decreased STAT3, Akt and mTOR protein expression levels in NCI-H460 cells. Additionally, the levels of the Bax, an apoptotic protein were increased than the control group, whereas the expression levels of anti-apoptotic proteins Bcl-2 and Bcl-xL were decreased than the control group. Protein level of IL-6 shows the reversible effect compared to viscothionin. Taken together, these results demonstrate that viscothionin exhibits potent anticancer effect in NSCLC through STAT3 inhibition, and could be considered a natural agent of lung cancer therapy.
- non-small cell lung cancer
How to Cite
Lu C, Onn A, Vaporciyan A. Chapter 78: Cancer of the lung. 8th Ed. editor^editors.: Holland-Frei Cancer Medicine; 2010. p.978-1-60795-014-1.
Zappa C, Mousa SA. Non-small cell lung cancer: Current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288-300.
Boudny V, Kovarik J. JAK/STAT signaling pathways and cancer. Janus kinases/ signal transducers and activators of transcription. Neoplasma. 2002;49(6):349-355.
O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency and cancer. N Engl J Med. 2013;368(2): 161-170.
Yu H, Jove R. The STATs of cancer--new molecular targets come of age. Nat Rev Cancer. 2004;4(2):97-105.
Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009;15(2):103-113.
Ara T, Song L, Shimada H, Keshelava N, Russell HV, Metelitsa LS, et al. Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res. 2009;69(1):329-337.
Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: Direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 2002;62(22):6659-6666.
Lin L, Liu A, Peng Z, Lin HJ, Li PK, Li C, et al. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res. 2011;71(23):7226-7237.
Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene. 2001;20(20): 2499-2513.
Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer. 2009;9(11): 798-809.
Szczesny TJ, Slotwinski R, Stankiewicz A, Szczygiel B, Zaleska M, Kopacz M. Interleukin 6 and interleukin 1 receptor antagonist as early markers of complications after lung cancer surgery. Eur J Cardiothorac Surg. 2007;31(4):719-724.
Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol. 2014;26(1):54-74.
Kienle GS, Kiene H. Review article: Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: A systematic review of controlled clinical studies. Integr Cancer Ther. 2010;9(2):142-157.
Pearl PL, Drillings IM, Conry JA. Herbs in epilepsy: Evidence for efficacy, toxicity and interactions. Semin Pediatr Neurol. 2011;18(3):203-208.
Olsnes S, Stirpe F, Sandvig K, Pihl A. Isolation and characterization of viscumin, a toxic lectin from Viscum album L. (mistletoe). J Biol Chem. 1982;257(22): 13263-13270.
Khil LY, Kim W, Lyu S, Park WB, Yoon JW, Jun HS. Mechanisms involved in Korean mistletoe lectin-induced apoptosis of cancer cells. World J Gastroenterol. 2007;13(20):2811-2818.
Kim S, Lee D, Kim JK, Kim JH, Park JH, Lee JW, et al. Viscothionin isolated from Korean mistletoe improves nonalcoholic fatty liver disease via the activation of adenosine monophosphate-activated protein kinase. J Agric Food Chem. 2014;62(49):11876-11883.
Lee H, Jeong AJ, Ye SK. Highlighted STAT3 as a potential drug target for cancer therapy. BMB Rep. 2019;52(7):415-423.
Kortylewski M, Yu H. Role of Stat3 in suppressing anti-tumor immunity. Curr Opin Immunol. 2008;20(2):228-233.
Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer. 2005;41(16):2502-2512.
Kamimura D, Ishihara K, Hirano T. IL-6 signal transduction and its physiological roles: The signal orchestration model. Rev Physiol Biochem Pharmacol. 2003;149:1-38.
Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 1998;334(Pt 2):297-314.
Bloem A, Lockhorst H. Bcl-2 antisense therapy in multiple myeloma. Pathol Biol (Paris). 1999;47(2):216-220.
Abstract View: 826 times
PDF Download: 446 times